The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders

Wild-type EGFR Is Stabilized by Direct Interaction with HSP90 in Cancer Cells and Tumors

(2015) Aarif Ahsan et al.   NEOPLASIA

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dacomitinib, a new therapy for the treatment of non-small cell lung cancer

(2013) Christina Brzezniak et al.   EXPERT OPINION ON PHARMACOTHERAPY

ALKin Lung Cancer: Past, Present, and Future

(2013) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non-Small Cell Lung Cancer Expressing EML4-ALK

(2013) Y. Sun et al.   MOLECULAR CANCER THERAPEUTICS

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC

(2013) Francesca Casaluce et al.   Targeted Oncology

Antiangiogenic agents in the management of non-small cell lung cancer

(2012) Charu Aggarwal et al.   CANCER BIOLOGY & THERAPY

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

(2012) J. M. Heuckmann et al.   CLINICAL CANCER RESEARCH

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

(2012) Tudor Ciuleanu et al.   LANCET ONCOLOGY

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Treating ALK-positive lung cancer—early successes and future challenges

(2012) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

MET: a promising anticancer therapeutic target

(2012) Solange Peters et al.   Nature Reviews Clinical Oncology

ERK1/2 MAP kinases: Structure, function, and regulation

(2012) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition

(2012) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance

(2012) C. M. Lovly et al.   Science Translational Medicine

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

ALKoma: A Cancer Subtype with a Shared Target

(2012) Hiroyuki Mano   Cancer Discovery

Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas

(2012) Zunyan Dai et al.   Molecular Cytogenetics

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors

(2011) C. M. Lovly et al.   CANCER RESEARCH

Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene

(2011) A. K. Murugan et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

(2011) J. M. Heuckmann et al.   CLINICAL CANCER RESEARCH

Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer

(2011) Takayuki Kosaka et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

(2011) J. Jean Cui et al.   JOURNAL OF MEDICINAL CHEMISTRY

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

(2011) Vince D. Cataldo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma

(2011) Jianjun Gao et al.   PHARMACOLOGICAL RESEARCH

Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment

(2011) Govardhanan Nagaiah et al.   Journal of Oncology

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

(2010) Christian C. Lee et al.   BIOCHEMICAL JOURNAL

Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors

(2010) Roberto T. Bossi et al.   BIOCHEMISTRY

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

MET signalling: principles and functions in development, organ regeneration and cancer

(2010) Livio Trusolino et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

(2010) James E. Butrynski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aggressive Lymphomas

(2010) Georg Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protein kinases: evolution of dynamic regulatory proteins

(2010) Susan S. Taylor et al.   TRENDS IN BIOCHEMICAL SCIENCES

Anaplastic lymphoma kinase: signalling in development and disease

(2009) Ruth H. Palmer et al.   BIOCHEMICAL JOURNAL

Defining the conserved internal architecture of a protein kinase

(2009) Alexandr P. Kornev et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

(2009) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation

(2009) Fabio Zuccotto et al.   JOURNAL OF MEDICINAL CHEMISTRY

Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers

(2009) E. Lin et al.   MOLECULAR CANCER RESEARCH

Developing c-MET pathway inhibitors for cancer therapy: progress and challenges

(2009) Xiangdong Liu et al.   TRENDS IN MOLECULAR MEDICINE

Emerging ethnic differences in lung cancer therapy

(2008) I Sekine et al.   BRITISH JOURNAL OF CANCER

Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials

(2008)   JOURNAL OF CLINICAL ONCOLOGY

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

(2008) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

(2008) Eric Winer et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE

Activation of tyrosine kinases by mutation of the gatekeeper threonine

(2008) Mohammad Azam et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

(2008) Bruce D. Cheson et al.   NEW ENGLAND JOURNAL OF MEDICINE